BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cancer Epigenetics Society - ECPv5.3.2.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cancer Epigenetics Society
X-ORIGINAL-URL:https://ces.b2sg.org
X-WR-CALDESC:Events for Cancer Epigenetics Society
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20191027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190324
DTEND;VALUE=DATE:20190426
DTSTAMP:20260729T170838
CREATED:20190324T194116Z
LAST-MODIFIED:20190324T194116Z
UID:21132-1553385600-1556236799@ces.b2sg.org
SUMMARY:Senior Scientist\, Molecular Discovery
DESCRIPTION:This senior scientist will join the Integrative Biotechnology Group of the Pfizer Oncology Research Department where s/he will apply functional genomics to study cellular mechanisms that impact tumor response to late stage oncology pipeline assets. \nThe qualified candidate should be a highly motivated\, creative\, and collaborative individual with strong interest and publication record relevant to tumor intrinsic / extrinsic signaling regulating cell cycle progression\, epigenetics\, and/or senescence response. The candidate must be flexible to study novel mechanisms underlying tumor vulnerabilities discovered from functional genomics screening efforts. This role includes developing and applying flow cytometry based biological endpoint assays to enable prioritization of screen hits that elicit desired outcome. \nThe successful candidate must have strong communication skills and will be expected to present their research to multidisciplinary teams\, senior management\, and at external scientific meetings. \nROLE RESPONSIBILITIES  \n\nDevelop and execute assays for in vitro / in vivo synthetic lethal functional genomics screens in relevant cancer models to discover genes that impact sensitivity or resistance to late stage oncology compounds.\nPrioritize drug discovery opportunities by integrating screen results with knowledge gained from publicly available datasets and multi-omics profiling of tumor response to small molecule inhibitors.\nCollaborate with a diverse team of cancer and molecular biologists to validate and determine the mechanism of action of prioritized targets.\nIncorporate advances in CRISPR/RNAi technologies to maintain cutting edge functional genomics platform.\nPresent key findings that highlight research progress and opportunities to senior management and at internal meetings.\nContinue excellent publication and presentation record by publishing research discoveries in high impact journals and presenting at external scientific conferences.\n\nBASIC QUALIFICATIONS  \n\nPh.D. in Cell Biology or related discipline and 3+ years of academic experience at the postdoctoral level or 2+ years of industry experience in cancer research.\nBroad understanding of and advanced technical expertise in research of signaling pathways that underlie cell cycle progression\, epigenetics\, and/or mechanisms that govern senescence.\n\nPREFERRED QUALIFICATIONS \n\nExperience executing pooled CRISPR/RNAi screens in cancer models in vitro and / or in vivo.\nStrong technical expertise in flow cytometry / sorting.\nDeveloped/applied biological endpoint assays to gain mechanistic insights into the consequences of gene knockdown or inhibition.\nExperience working with 2D and 3D mammalian cell culture systems.\nExpert molecular biology skills as well as expertise in immunofluorescence\, immunoprecipitation\, transgene mutagenesis / expression\, western blot\, and Q-PCR.\nSignificant impact in field of study as demonstrated by publications in top tier peer-reviewed research journals.
URL:https://ces.b2sg.org/event/24mar19/
LOCATION:Pfizer – Pearl River\, NY\, 401 North Middletown Road\, Pearl River\, NY\, 10965\, United States
CATEGORIES:Jobs
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2018/05/pfizer_new_logo.jpg
END:VEVENT
END:VCALENDAR